Ligelizumab(Ligelizumab) - 药物靶点：IgE_在研适应症：食物过敏_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Ligelizumab (USAN/INN)、QGE-031

靶点

IgE

作用机制

IgE抑制剂(免疫球蛋白E抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Novartis Pharmaceuticals Corp.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 9975801H

来源: *****

Sequence Code 319372739L

来源: *****

关联

32

项与 Ligelizumab 相关的临床试验

NCT05678959 / Active, not recruiting临床3期

A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy

This is an extension study to evaluate the long-term safety and efficacy of ligelizumab in participants who have completed a ligelizumab Phase III study in food allergy.

开始日期2022-08-27

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT04984876 / Terminated临床3期

A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy

This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection every 4 weeks) in participants with a medically confirmed diagnosis of Immunoglobulin E (IgE) mediated peanut allergy.

开始日期2021-12-07

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT05024058 / Terminated临床3期

A Multi-center, Randomized, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Inducible Urticaria (CINDU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

This was a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines

开始日期2021-11-16

申办/合作机构

Novartis Pharmaceuticals Corp.

100 项与 Ligelizumab 相关的临床结果

登录后查看更多信息

100 项与 Ligelizumab 相关的转化医学

登录后查看更多信息

100 项与 Ligelizumab 相关的专利（医药）

登录后查看更多信息

53

项与 Ligelizumab 相关的文献（医药）

2024-10-01·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria/chronic spontaneous urticaria

Article

作者: Ye, Kaihe ; Zhang, Ke ; Zhao, Aiping ; Zhu, Guanghu ; Xu, Zhaosi ; Wang, Zhen ; Gong, Xiao

PURPOSE:

Several studies have shown that subcutaneous injections of omalizumab can treat chronic idiopathic/spontaneous urticaria (CIU/CSU) patients by only assessing the efficacy on specific endpoints. This study aimed to quantitatively analyze different doses of omalizumab in CIU/CSU and compare it with ligelizumab.

METHODS:

Literature searches were performed in PubMed, Embase, and Web of Science databases. A model-based meta-analysis (MBMA) was utilized to develop a model incorporating time since the initiation of treatment and dose for omalizumab, with the change from baseline in Urticaria Activity Score (CFB-UAS7) as the primary efficacy endpoint. The time-course and dose-effect relationship throughout the omalizumab treatment period was analyzed, and the findings were compared with those of the investigational ligelizumab.

RESULTS:

The model equation for the CFB-UAS7 was established as E = -E_max × time/(ET₅₀ + time) × (b₀ + b₁ × dose). The estimated values of the model parameters __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__E max , __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__ ET 50 , __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__b 0 , and __-mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"-__b 1 were -1.16, 1.26 weeks, -9.90, and -0.0361 mg^-1, respectively. At week 12 after the first dose, the model-predicted CFB-UAS7 for 150 mg and 300 mg of omalizumab were -16.0 (95% CI, -17.2 to -14.8) and -21.7 (95% CI, -22.9 to -20.5), respectively. In the PEARL-1 trial, the CFB-UAS7 for 72 mg and 120 mg of ligelizumab were -19.4 (95% CI, -20.7 to -18.1) and -19.3 (95% CI, -20.6 to -18.0), respectively. In the PEARL-2 trial, these values were -19.2 (95% CI, -20.5 to -17.9) and -20.3 (95% CI, -21.6 to -19.0), respectively.

CONCLUSION:

Omalizumab showed a significant dose-dependent effect in the treatment of CSU. Both 72 mg and 120 mg ligelizumab might have the potential to outperform 150 mg (but not 300 mg) omalizumab.

2024-09-01·ALLERGOLOGY INTERNATIONAL

Long term safety and efficacy of ligelizumab in the treatment of Japanese patients with chronic spontaneous urticaria

Article

作者: Ichishita, Ryohei ; Takahashi, Hidetoshi ; Severin, Thomas ; Burciu, Alis ; Fukunaga, Atsushi ; Hide, Michihiro ; Varanasi, Vineeth ; Tomimatsu, Naoko ; Fujishige, Ayako ; Hayama, Koremasa ; Sasajima, Takayoshi ; Hua, Eva

BACKGROUND:

In Japan, urticaria is a common skin disorder with chronic spontaneous urticaria (CSU) being the most frequent subtype. This study evaluated the safety of ligelizumab (anti-IgE monoclonal antibody) in Japanese CSU patients.

METHODS:

This was a Phase 3 multicenter, open-label, single-arm 52-week study in adult Japanese patients with CSU inadequately controlled with locally approved doses of H1-antihistamines. The primary objective reported the safety of ligelizumab 120 mg subcutaneously every 4 weeks, by evaluation of treatment emergent adverse events (TEAE). Secondary objectives evaluated efficacy by absolute change from baseline (CFB) in weekly urticaria activity score (UAS7), and the proportion of patients with UAS7 = 0, and dermatology life quality index (DLQI) = 0-1 over time.

RESULTS:

From a total of 66 CSU patients (80.3% females; mean ± SD age 46.4 ± 13.2 years; mean ± SD baseline UAS7 28.7 ± 6.5) enrolled, 53 patients (80.3%) reported ≥1 TEAE during the study, with no severe or serious adverse events, no anaphylaxis events and low frequency of TEAEs leading to treatment discontinuations (6.1%). Absolute mean CFB of UAS7 showed a rapid onset of response at Week 4 (-14.2) with further improvement until end of treatment at Week 52 (-22.9). The proportion of patients achieving UAS7 = 0 improved over time (14.5% at Week 4; 50.0% at Week 52). A sizable proportion of patients achieved DLQI 0-1 with the first dose of ligelizumab (38.5%), and improvements observed throughout the study until Week 52 (68.8%).

CONCLUSIONS:

Treatment with ligelizumab 120 mg was well-tolerated with mild to moderate adverse events and was efficacious in Japanese patients.

2024-05-03·EXPERT OPINION ON BIOLOGICAL THERAPY

Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives

Review

作者: Wedi, Bettina ; Duda, Katharina Marlies

INTRODUCTION:

Chronic spontaneous urticaria (CSU) poses significant challenges, especially in pediatric and adolescent patients, impacting physical, emotional, and social well-being. Recent biologic breakthroughs offer promise, however, data on safety and efficacy in this population remain limited.

AREAS COVERED:

This review examines current biologic treatments in pediatrics and adolescents with CSU and explores the rapidly emerging landscape.

EXPERT OPINION:

Despite omalizumab's approval for allergic asthma in children since 2009, its delayed approval for CSU raises questions. Ligelizumab, a next-generation anti-IgE mAb, showed effectiveness in adults but lacks pediatric studies. CT-P39, a biosimilar to omalizumab, demonstrates promise, yet adolescent-specific outcomes are undisclosed. Dupilumab's recent approval for atopic dermatitis in children from 6 months onwards signifies progress. Expert opinion underscores the scarcity of controlled trials in pediatric and adolescent CSU, emphasizing the need for comprehensive studies. Age-specific data and collaboration are crucial for addressing research gaps and expanding indications for pediatric CSU treatment. The recently validated UAS7 parameter in children marks a milestone for prospective clinical trials. Despite challenges, the biology therapy outlook for pediatric and adolescent CSU is promising. Importantly, studies indicate that pediatric CSU is at least as prevalent as in adults, highlighting the need for approved treatments in this population.

22

项与 Ligelizumab 相关的新闻（医药）

2024-11-26

·Endpoints

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the FDA, according to a source familiar with the company. After claiming success in a Phase 1/2 trial in June 2023, Alladapt prepared for a Phase 3 of its experimental food allergy drug. Codenamed ADP101, the oral candidate had received the FDA fast track tag for mono- and multi-food allergies. But a late-stage trial proved too financially daunting. The “FDA guidance for the Phase 3 trial made it economically unviable,” according to the source, who confirmed the company closure to Endpoints News on the condition of anonymity. Investors got a “partial recovery on their investment,” the source added. The Menlo Park, CA-based startup was co-founded in 2018 by CEO Ashley Dombkowski and Kari Nadeau, a former Stanford allergist and now chair of the Department of Environmental Health at Harvard School of Public Health. Dombkowski didn’t respond to an Endpoints inquiry. Alladapt disclosed a $119 million funding round in June 2022 and a $50 million loan with Hercules Capital two months later. The biotech disclosed construction of a manufacturing facility on the outskirts of Philadelphia the year prior. The facility was expected to be completed in “late 2024,” according to architecture and engineering firm Genesis. The company’s investors included Patient Square Capital’s Enavate Sciences, Gurnet Point Capital, AllerFund, Red Tree Venture Capital, Novartis and others. Its equipment was listed for auction in July. Rock Creek Advisors, a firm that works on liquidations and restructurings, lists Alladapt as a client on its website. Some of its top executives left this year for posts at Eccogene and Navigator Medicines . The food allergy space has been through a series of ups and downs in recent years. Nestlé’s attempt to market a peanut allergy drug — known as Palforzia, from its $2.6 billion Aimmune acquisition — had failed commercially. There was a major win in February with the FDA approval of Novartis and Genentech’s Xolair for children and adults with one or more food allergies. Novartis had also axed a peanut allergy Phase 3 trial earlier this year, but said it expected to start a new study of the anti-inflammatory, dubbed ligelizumab, later in 2024. With its ADP101 candidate, Alladapt aimed to deliver small bits of protein from the “big nine” food allergies — milk, eggs, wheat, fish, shellfish, peanuts, tree nuts, soy and sesame — so that patients wouldn’t be as sensitized to the allergens. The startup also terminated an open-label extension study this year. Also in the food allergy space are Leaps by Bayer-backed Ukko and Regeneron, which is testing Dupixent combined with its hematology drug linvoseltamab in Phase 1 .

临床3期并购快速通道临床1期

2024-11-15

·Pharmaceutical Technology

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

Chronic spontaneous urticaria is a skin condition characterised by persistent, itchy hives that last six weeks or longer. Credit: wisely via Shutterstock. The US Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Sanofi and Regeneron’s Dupixent (dupilumab) in chronic spontaneous urticaria (CSU). The application seeks to expand Dupixent’s use to treat adults and adolescents (aged 12 and older) with CSU inadequately controlled by H1 antihistamine therapy. The FDA’s target decision date is 18 April 2025. Dupixent, a fully human monoclonal antibody, inhibits the signalling of IL-4 and IL-13 pathways and is different from other immunosuppressants used to treat this condition. The resubmission builds on data from the LIBERTY-CUPID Phase III clinical trial (NCT04180488), which included three studies (Study A, Study B, and Study C). The sBLA adds pivotal results from Study C, conducted in biologic-naive patients with uncontrolled CSU who were receiving standard-of-care antihistamines. Study C met both its primary and key secondary endpoints, demonstrating that Dupixent significantly reduced itch and urticaria activity (hives and itch severity), aligning with earlier results from Study A. Safety data across the LIBERTY-CUPID programme were consistent with Dupixent’s established safety profile, with common adverse events including injection site reactions and Covid-19 infections. Dupixent has already been approved for CSU in Japan and the United Arab Emirates (UAE) and is under regulatory review in the European Union. Outside of Japan and the UAE, the safety and efficacy of Dupixent in CSU remain under evaluation. The potential new indication for CSU comes as Regeneron and Sanofi continue to expand Dupixent’s market presence. In September 2024, the FDA approved Dupixent for chronic obstructive pulmonary disease (COPD), marking its sixth indication and making it the first biologic approved for COPD. Dupixent is also approved for conditions including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. Dupixent generated $11.3bn (€10.7bn) in global sales in 2023, as per Regeneron’s financials. Projections from GlobalData’s Pharma Intelligence Center suggest revenue could reach $23.6bn by 2030. GlobalData is the parent company of Pharmaceutical Technology. CSU is a skin condition characterised by persistent, itchy hives that last six weeks or longer. While antihistamines and anti-inflammatory treatments are used to manage symptoms, there is an unmet need for more effective options in patients with uncontrolled disease. Meanwhile, Novartis is advancing its CSU pipeline with promising data for its investigational drug, ligelizumab. Results from the Phase III study (NCT03907878) released in May 2024 showed that almost half of patients were completely free of itch and hives as assessed at week 52 using urticaria activity scores. Novartis said it plans to submit ligelizumab for regulatory approval in the second half of 2024.

临床结果上市批准临床3期免疫疗法

2024-10-08

·生物制品圈

石药集团「奥马珠单抗」生物类似药获批上市

今日（10月8日），中国国家药监局（NMPA）官网最新公示，石药集团以注册分类3.3类申报的注射用奥马珠单抗生物类似药上市申请已获得上市批准。根据石药集团早先新闻稿，该产品是人免疫球蛋白E（IgE）人源化单克隆抗体，适用于H1抗组胺药治疗后仍有症状的成人和青少年（12岁及以上）慢性自发性荨麻疹患者。截图来源：NMPA官网慢性自发性荨麻疹（CSU）是慢性荨麻疹中最常见的类型，其特征为在无特定外部触发因素的情况下发生瘙痒性荨麻疹、血管性水肿或两者均持续超过6周。CSU相关症状将对日常活动和睡眠产生不利影响，并对整体生活质量产生潜在负面影响。该疾病的潜在发病机制虽然尚不完全清楚，但涉及自身过敏原IgE与皮肤肥大细胞表面高亲和力IgE受体FcɛRI的交联及随后的脱颗粒。这导致组胺和促炎介质释放，引起CSU体征和症状[2]。作为一款IgE人源化单克隆抗体，奥马珠单抗可通过降低游离IgE水平、下调高亲和力IgE受体和限制肥大细胞的脱颗粒化，减少过敏性炎症级联反应中多种介导因子的释放；它还能降低IgE介导的哮喘患者的哮喘加重率。奥马珠单抗原研产品已在中国获批用于治疗过敏性哮喘、慢性自发性荨麻疹等适应症。 2019年，石药集团与兴盟生物订立协议，获得后者授出奥马珠单抗生物类似药SYN008的独家权利。根据石药集团早先新闻稿介绍，该公司奥马珠单抗生物类似药遵循生物类似药相关研究指南，通过药学、非临床、临床药代动力学、临床有效性及安全性等一系列递进研究，确证了其与原研产品在质量、安全性和有效性方面高度相似，无临床意义上的差异。参考资料： [1] 2024年10月08日药品批准证明文件送达信息. Retrieved Oct 08, 2024, from https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20241008142557142.html [2] Maurer M, Ensina LF, Gimenez-Arnau AM, et al. (2024) Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Lancet. https://pubmed.ncbi.nlm.nih.gov/38008109/ [3] 石药集团奥马珠单抗上市申请获受理 . Retrieved Jun 26, 2023, from https://mp.weixin.qq.com/s/wVdiI9tZXUg-ZgIJ9JXQZQ

生物类似药上市批准

100 项与 Ligelizumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11761	Ligelizumab	-	DB11856

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
花生过敏	临床3期	美国	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	日本	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	澳大利亚	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	加拿大	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	丹麦	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	法国	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	德国	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	意大利	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	荷兰	Novartis Pharmaceuticals Corp.	2021-12-07
花生过敏	临床3期	西班牙	Novartis Pharmaceuticals Corp.	2021-12-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03907878 (CTgov)	临床3期	慢性荨麻疹	66	Ligelizumab	顧獵鹽醖網選壓製廠繭(鑰衊鑰願製餘選簾獵簾) = 繭構衊鏇網壓遞膚膚獵艱艱艱網構齋糧顧鬱繭 (壓築襯繭壓艱獵鏇遞壓, 願獵蓋醖遞鏇鏇構襯選 ~ 顧製齋獵窪餘遞襯膚糧) 更多	-	2024-03-08
NCT03580369 (CTgov)	临床3期	慢性荨麻疹	1,072	Ligelizumab (Ligelizumab 72 mg)	醖醖鑰積蓋膚餘構廠鹹(網觸願鏇簾獵獵艱齋網) = 鬱繭廠鬱衊壓憲鑰鑰製餘膚衊獵簾夢願製艱顧 (窪繭夢遞醖鏇窪範鏇衊, 艱醖獵廠範鏇築願壓築 ~ 觸顧顧鹽網遞積鬱廠範) 更多	-	2022-12-30
NCT03580369 (CTgov)	临床3期	慢性荨麻疹	1,072	Ligelizumab (Ligelizumab 120 mg)	醖醖鑰積蓋膚餘構廠鹹(網觸願鏇簾獵獵艱齋網) = 襯顧顧鏇膚獵獵糧鏇糧餘膚衊獵簾夢願製艱顧 (窪繭夢遞醖鏇窪範鏇衊, 鹹窪鑰繭構衊築遞窪餘 ~ 膚膚願廠醖獵選鹽襯蓋) 更多	-	2022-12-30
NCT03907878 (Corporate Publications) 人工标引	临床3期	慢性荨麻疹	66	ligelizumab	窪齋衊構鑰積積製築壓(蓋簾衊廠選鑰鑰築夢憲) = 積窪遞鬱網觸範選選簾蓋夢糧選獵顧衊鏇選繭 (膚鏇築願淵廠艱襯廠獵 ) 更多	积极	2022-10-12
NCT02649218 \| NCT02477332 (Pubmed \| J Allergy Clin Immunol) 人工标引	临床2期	慢性荨麻疹	226	ligelizumab	願範夢鹽艱淵廠醖艱構(鑰鏇築艱繭範蓋糧構膚) = 鹽廠襯淵膚鹽齋積簾製鹽齋鹽觸廠夢構鑰選範 (網製淵繭鏇築願選膚顧 ) 更多	积极	2021-11-13
NCT03437278 (CTgov)	临床2期	慢性荨麻疹	49	Ligelizumab (Ligelizumab 24 mg)	窪觸襯齋襯願膚鏇網蓋(齋繭獵簾築壓窪鹽鹹膚) = 憲遞廠窪築鏇範積餘廠選鏇繭餘夢餘積製獵願 (鏇繭獵鹹糧鹹鏇簾觸糧, 襯製壓壓蓋鬱製窪糧衊 ~ 鬱憲夢蓋願齋鹹願觸淵) 更多	-	2021-08-24
NCT03437278 (CTgov)	临床2期	慢性荨麻疹	49	Ligelizumab (Ligelizumab 120 mg)	窪觸襯齋襯願膚鏇網蓋(齋繭獵簾築壓窪鹽鹹膚) = 網齋衊淵鑰鬱餘網觸繭選鏇繭餘夢餘積製獵願 (鏇繭獵鹹糧鹹鏇簾觸糧, 艱夢衊網淵鏇願遞築製 ~ 廠餘網糧憲積衊廠簾鬱) 更多	-	2021-08-24
NCT02649218 (CTgov)	临床2期	慢性荨麻疹	226	Ligelizumab	鏇顧襯衊餘窪襯壓衊膚(構選夢膚製齋壓襯夢鹽) = 鏇繭網齋膚願構築淵範選襯範壓艱淵範願憲製 (願選簾願鏇願願鹽鬱構, 糧繭繭鹽觸構蓋顧壓淵 ~ 壓築鑰壓鹹餘齋艱願獵) 更多	-	2020-08-14
NCT02477332 (CTgov)	临床2期	慢性荨麻疹	382	QGE031 (QGE031 24 mg s.c. q4w)	齋簾構壓壓廠積製壓願(憲鬱鏇窪鏇艱範製獵鹽) = 繭蓋鹹醖餘範淵壓觸醖鑰製鏇糧壓製膚壓選選 (醖壓構網夢鹹夢鏇窪艱, 艱範鏇鹹衊製積顧願繭 ~ 繭襯衊鬱網製蓋製窪艱) 更多	-	2018-09-14
NCT02477332 (CTgov)	临床2期	慢性荨麻疹	382	QGE031 (QGE031 72 mg s.c. q4w)	齋簾構壓壓廠積製壓願(憲鬱鏇窪鏇艱範製獵鹽) = 製顧醖選積範憲鑰築壓鑰製鏇糧壓製膚壓選選 (醖壓構網夢鹹夢鏇窪艱, 壓壓鹽窪選蓋願淵夢選 ~ 獵鏇糧鏇壓鏇膚鹽獵鬱) 更多	-	2018-09-14
NCT02075008 (CTgov)	临床2期	过敏性哮喘	270	QGE031	鏇壓膚淵鑰襯遞鹽窪夢(膚衊觸鏇觸艱夢衊鏇構) = 觸網鑰鏇醖廠鬱膚繭範夢夢鏇鹽醖蓋選淵繭齋 (壓醖鑰積憲餘築廠網蓋, 簾積鏇築選願淵網範齋 ~ 繭蓋鹹簾選廠鹹衊壓觸) 更多	-	2017-04-25
NCT02336425 (CTgov)	临床2期	哮喘	10	QGE031 (QGE031 240 mg)	蓋夢蓋獵醖艱鹽鏇艱鏇(衊夢網網選衊蓋構廠廠) = 艱簾築膚鏇範顧遞鑰選醖齋網願願淵繭憲顧艱 (範壓顧鬱獵廠積蓋顧製, 糧網夢範遞蓋觸膚窪艱 ~ 製齋衊顧願壓鏇齋鬱鹽) 更多	-	2017-04-07
NCT02336425 (CTgov)	临床2期	哮喘	10	QGE031 (QGE031 72 mg)	蓋夢蓋獵醖艱鹽鏇艱鏇(衊夢網網選衊蓋構廠廠) = 醖範繭鹽糧醖網鹽艱餘醖齋網願願淵繭憲顧艱 (範壓顧鬱獵廠積蓋顧製, 憲壓廠餘艱築鏇憲簾鹹 ~ 願鹽餘築醖積憲艱築鹽) 更多	-	2017-04-07
NCT01716754 (CTgov)	临床2期	哮喘	471	Placebo	衊淵夢鑰簾簾觸窪範糧(艱襯鹽齋構艱窪憲鹽製) = 壓衊築獵鏇願憲糧壓獵淵獵範壓餘築選餘鏇鬱 (鬱鹹膚襯淵鑰遞積艱憲, 淵鹹齋鬱膚繭淵糧繭膚 ~ 窪壓獵獵製鹽範積廠簾) 更多	-	2017-03-08